Our current clinical understanding of Candida biofilms: where are we two decades on?
APMIS, Volume 131, Issue 11, Page 636-653, November 2023., 2023 Clinically we have been aware of the concept of Candida biofilms for many decades, though perhaps without the formal designation. Just over 20 years ago the subject emerged on the back of progress made from the bacterial biofilms, and academic progress pace has continued to mirror the bacterial biofilm community, albeit at a decreased volume.
Gordon Ramage +5 more
wiley +1 more source
Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin [PDF]
, 2023 Introduction: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous ...
De Rosa, Francesco Giuseppe +6 more
core +8 more sources
Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]
F1000Research, 2022 Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs +2 more
doaj +1 more source
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
APMIS, Volume 131, Issue 11, Page 654-667, November 2023., 2023 The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney +4 more
wiley +1 more source
Internal Medicine Journal, Volume 53, Issue 8, Page 1489-1491, August 2023., 2023 Abstract Scedosporium and Lomentospora species are environmental moulds that are virulent in immunocompromised hosts and rarely cause bloodstream infection (BSI). Patients with Scedosporium and Lomentospora species BSI were identified by the state public laboratory service in Queensland, Australia, over a 20‐year period.
Adam G. Stewart +5 more
wiley +1 more source
Clinical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with candidemia caused by Candida auris : results from a Phase 2 trial [PDF]
, 2023 DATA AVAILABILITY: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified ...
Bien, Paul A. +9 more
core +1 more source
A One Health approach to overcoming fungal disease and antifungal resistance
WIREs Mechanisms of Disease, Volume 15, Issue 4, July/August 2023., 2023 A One Health approach to fungal disease integrates environment, animal, and human health to uncover new antifungal therapies and overcome the increasing threat of antifungal resistance. Abstract The global burden of fungal disease poses a substantial threat to human, animal, and environmental health, endangering both human and livestock populations and
Michael Woods +2 more
wiley +1 more source
Antifungal chemotherapies and immunotherapies for the future
Parasite Immunology, Volume 45, Issue 2, February 2023., 2023 Abstract Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response.
Darius Armstrong‐James
wiley +1 more source
Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes [PDF]
Antimicrobial Agents and Chemotherapy, 2021 We evaluated the in vitro activity of manogepix against Fusarium oxysporum and Fusarium solani species complex (FOSC and FSSC, respectively) isolates per CLSI document M38 broth microdilution methods.
Hamid Badali +7 more
openaire +2 more sources
A Bibliometric Review on Candida auris of the First Fifteen Years of Research (2009‐2023)
BioMed Research International, Volume 2023, Issue 1, 2023., 2023 Introduction. Candida auris is a relatively novel pathogen first described in 2009 in Japan. It has increased its presence worldwide, becoming a public health concern due to its innate resistance to antifungals and outbreak potential. Methods.
Hiram Villanueva-Lozano +5 more
wiley +1 more source